ArticleFrontiers in neurology
Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrospinal fluid (CSF) specific oligoclonal bands (OCB) are a key diagnostic marker in multiple sclerosis (MS). Recent studies suggest that OCB reduction may reflect treatment efficacy and propose it as a potential endpoint in trials with chimeric antigen receptor (CAR) T-cell therapy. However, the prognostic value of baseline OCB count remains unclear. This study analyzed data from 454 persons (314 had MS, 140 clinically isolated syndrome). OCB analysis was performed by isoelectric focusing in polyacrylamide gel, followed by silver staining. The correlation of the number of OCBs with clinical and paraclinical parameters as well as follow-up outcomes was evaluated. Our results showed that in OCB positive persons with MS, the median number of CSF specific bands was 19. No significant correlation was found between OCB count and age, sex, initial EDSS, or MRI lesion load. OCB count also did not predict relapse risk or EDSS progression. However, strong correlations were observed with intrathecal synthesis of IgG and kappa free light chains. Therefore, our conclusion is that OCB count does not reflect clinical disease activity at diagnosis nor predict clinical progression within the observed median follow-up period of 9 months. Whether a decrease in OCB count indicates reduced humoral immune response in the CNS under certain therapies remains unclear and requires further prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.